Northern Trust Corp Esperion Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,474,422 shares of ESPR stock, worth $3.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,474,422

Previous 405,038 264.02%

Holding current value

$3.55 Million

Previous $899,000 170.52%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.61 - $2.73 $1.72 Million - $2.92 Million	1,069,384 Added 264.02%	1,474,422 $2.43 Million
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $177,304 - $312,209	96,361 Added 31.22%	405,038 $899,000
Q1 2024 May 14, 2024	BUY	$2.02 - $3.02 $145,609 - $217,693	72,084 Added 30.47%	308,677 $827,000
Q4 2023 Feb 13, 2024	BUY	$0.73 - $3.08 $5,754 - $24,279	7,883 Added 3.45%	236,593 $707,000
Q3 2023 Nov 13, 2023	BUY	$0.96 - $1.79 $64,780 - $120,789	67,480 Added 41.85%	228,710 $224,000
Q2 2023 Aug 11, 2023	SELL	$1.2 - $1.76 $618,110 - $906,561	-515,092 Reduced 76.16%	161,230 $224,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $16,408 - $82,044	11,239 Added 1.69%	676,322 $1.08 Million
Q4 2022 Feb 13, 2023	BUY	$5.09 - $8.5 $422,851 - $706,137	83,075 Added 14.27%	665,083 $4.14 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $78,000 - $116,356	14,312 Added 2.52%	582,008 $3.9 Million
Q2 2022 Aug 12, 2022	BUY	$4.77 - $6.67 $199,653 - $279,179	41,856 Added 7.96%	567,696 $3.61 Million
Q1 2022 May 13, 2022	BUY	$3.34 - $5.56 $630,201 - $1.05 Million	188,683 Added 55.96%	525,840 $2.44 Million
Q4 2021 Feb 08, 2022	BUY	$4.81 - $11.92 $203,535 - $504,394	42,315 Added 14.35%	337,157 $1.69 Million
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $204,641 - $385,643	-18,046 Reduced 5.77%	294,842 $3.55 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $28.71 $154,482 - $228,617	7,963 Added 2.61%	312,888 $6.62 Million
Q1 2021 May 12, 2021	SELL	$25.12 - $36.89 $510,413 - $749,567	-20,319 Reduced 6.25%	304,925 $8.55 Million
Q4 2020 Feb 11, 2021	SELL	$24.2 - $35.76 $310,316 - $458,550	-12,823 Reduced 3.79%	325,244 $8.46 Million
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $456,942 - $772,465	-14,655 Reduced 4.15%	338,067 $12.6 Million
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $1.17 Million - $1.99 Million	38,789 Added 12.36%	352,722 $18.1 Million
Q1 2020 May 14, 2020	BUY	$27.44 - $73.84 $97,988 - $263,682	3,571 Added 1.15%	313,933 $9.9 Million
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $271,872 - $459,417	-7,680 Reduced 2.41%	310,362 $18.5 Million
Q3 2019 Nov 13, 2019	BUY	$34.47 - $47.53 $872,780 - $1.2 Million	25,320 Added 8.65%	318,042 $11.7 Million
Q2 2019 Aug 13, 2019	BUY	$40.1 - $52.33 $107,828 - $140,715	2,689 Added 0.93%	292,722 $13.6 Million
Q1 2019 May 13, 2019	BUY	$40.11 - $53.57 $88,482 - $118,175	2,206 Added 0.77%	290,033 $11.6 Million
Q4 2018 Feb 12, 2019	SELL	$36.99 - $59.11 $12.5 Million - $20 Million	-338,812 Reduced 54.07%	287,827 $13.2 Million
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $1.49 Million - $1.88 Million	36,535 Added 6.19%	626,639 $27.8 Million
Q2 2018 Sep 18, 2018	SELL	$36.2 - $76.4 $58,716 - $123,920	-1,622 Reduced 0.27%	590,104 $23.1 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $446,128 - $941,553	12,324 Added 2.13%	591,726 $23.2 Million
Q1 2018 May 09, 2018	BUY	$65.94 - $80.76 $331,348 - $405,819	5,025 Added 0.87%	579,402 $41.9 Million
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $153,883 - $238,702	-3,540 Reduced 0.61%	574,377 $37.8 Million
Q3 2017 Nov 13, 2017	BUY	$43.8 - $52.77 $25.3 Million - $30.5 Million	577,917	577,917 $29 Million

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Esperion Therapeutics, Inc. Transaction History